Tamtam Try Tamtam free
AbbVie logo

AbbVie account plan

Biopharmaceutical medicine creation

At a glance

AbbVie is a US biopharmaceutical company in immunology, neuroscience, oncology and aesthetics: $61.2 billion 2025 net revenues, about 57,000 employees.

AbbVie is a research-based biopharmaceutical company, spun off from Abbott Laboratories on January 1, 2013, with leadership positions in immunology, neuroscience, oncology and aesthetics, plus eye care and other products. It markets mainly to prescribers, sells through wholesalers, specialty pharmacies, health care facilities and government agencies, and reports a single global business segment. FY2025 net revenues were $61.2 billion, up 8.6%, with the United States at $46,603 million; operating earnings were $15.1 billion and operating cash flow $19.0 billion. It employed approximately 57,000 people in over 70 countries at December 31, 2025. Robert A. Michael is Chairman and CEO.

Business units

Strategic priorities

Grow Skyrizi and Rinvoq into the 2030s
2026 guidance is $21.7 billion for Skyrizi and $10.1 billion for Rinvoq; new Rinvoq indications in vitiligo and alopecia areata are expected to approach $2 billion of peak sales, and Skyrizi regulatory data protection runs to 2031.
Build neuroscience into a second engine
Neuroscience guidance is $12.7 billion for 2026, with Parkinson's (Vyalev, Duodopa, tavapadon) and migraine each targeted above $5 billion of peak sales.
High single-digit growth through 2029
Management targets high single-digit revenue growth through 2029, with no significant losses of exclusivity until the next decade; 2026 revenue guidance was raised to approximately $67.6 billion.
External innovation and obesity
Over $8 billion invested in external innovation in two years across more than 30 deals, in immunology, neuroscience, oncology and obesity, as a new source of growth; the pipeline holds approximately 90 programs, approximately 60 in mid- and late-stage development.
U.S. investment pledge
The January 2026 agreement with the U.S. government commits low Medicaid prices, direct-to-patient offerings and $100 billion of U.S. R&D and capital investment over the next decade, in exchange for a three-year exemption from tariffs and future price mandates.

Latest results

In Q2 2026, net revenues were $16,990 million, up 10.2% (9.5% at constant currency), and first-half revenues $32.0 billion, up 11.2%. Q2 net earnings attributable to AbbVie were $3,613 million against $938 million a year earlier, and the gross margin rose to 75% of net revenues on lower amortisation. Skyrizi reached $5,505 million (+24.4%) and Rinvoq $2,525 million (+24.5%), while Imbruvica fell 29.4%. Full-year 2026 revenue guidance was raised to approximately $67.6 billion, with adjusted EPS guidance of $13.87 to $14.07 including $0.14 of Apogee dilution; Q3 guidance was net revenues of approximately $17.2 billion.

Investments and deals

Apogee Therapeutics acquisition
Definitive agreement in June 2026 to acquire Apogee for $135.11 per share, about $10.9 billion, adding biologics for atopic dermatitis, asthma and other inflammatory conditions; backed by a $10.0 billion 364-day term loan.
2025 business development
Acquired IPR&D and milestones of $5,016 million in 2025, including Capstan's in vivo CAR-T, Gilgamesh's bretisilocin, Ichnos Glenmark's ISB-2001, Gubra's amylin analog for obesity and ADARx's siRNA options.
RemeGen PD-1/VEGF license
License of RemeGen's RC148 bispecific for all markets excluding China, with $650 million upfront and up to $5.0 billion of milestones.
U.S. manufacturing expansion
A new API plant in Illinois, two new Illinois facilities for neuroscience and obesity medicines, a manufacturing campus in North Carolina, biologics and R&D expansion in Massachusetts, and an Arizona device plant acquisition closed in July 2026.

Challenges and risks

Humira biosimilar erosion
Humira fell 49.5% to $4,540 million in 2025, after nearly $16 billion of U.S. erosion since its loss of exclusivity, and access will decrease further in 2026.
U.S. government price setting
IRA government-set prices apply to Imbruvica from 2026, Vraylar and Linzess from 2027 and Botox from 2028, and low single-digit pricing headwinds are expected for Skyrizi and Rinvoq.
Weak aesthetics demand
Aesthetics category growth is expected to remain challenged in 2026 on economic headwinds, and the FDA issued a Complete Response Letter for trenibotulinumtoxinE on manufacturing questions.
Concentration and impairment risk
Skyrizi and Rinvoq made up approximately 42% of 2025 net revenues, and $52.6 billion of intangibles plus $35.6 billion of goodwill are subject to impairment.
Manufacturing and supply complexity
The 10-K names biologics manufacturing complexity, single-source suppliers and dependence on three U.S. wholesalers as risks.

What leadership says

“we are well-positioned to deliver high single-digit revenue growth through 2029.”

Robert A. Michael, Chairman and CEO · Q4 and full year 2025 earnings call, February 4, 2026

“we have plenty of capacity to invest in both internal and external innovation”

Robert A. Michael, Chairman and CEO · Q4 and full year 2025 earnings call, February 4, 2026

“We have ample financial capacity for more business development.”

Robert A. Michael, Chairman and CEO · On the Apogee acquisition, Q2 2026 earnings call, July 31, 2026

“regulatory data protection for SKYRIZI does not expire until 2031”

Robert A. Michael, Chairman and CEO · Q2 2026 earnings call, July 31, 2026

Where a supplier can help

U.S. manufacturing build-out
The $100 billion U.S. investment pledge and new plants in Illinois, North Carolina, Massachusetts and Arizona create demand for engineering, construction, equipment validation and manufacturing systems suppliers.
Launch support for new indications
Launches such as Rinvoq in vitiligo and alopecia areata, tavapadon in Parkinson's and Skyrizi subcutaneous induction in Crohn's fit commercial-execution partners: medical education, field force analytics and patient support.
Clinical development capacity
With approximately 60 programs in mid- and late-stage development and Phase 3 starts in colorectal and small cell lung cancer, CROs, trial technology and data vendors can support the pipeline priority.
Direct-to-patient and market access
The government agreement's direct-to-patient offerings and the IRA price-setting challenge make pharmacy, hub services and market access analytics providers relevant.
Injector training for aesthetics
The trenibotulinumtoxinE launch requires training 12,000 core injectors, an opening for training, practice-management and consumer marketing partners as aesthetics demand stays weak.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like AbbVie?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about AbbVie

What does AbbVie do?

AbbVie discovers, develops and sells medicines and aesthetic products, with leadership positions in immunology (Skyrizi, Rinvoq), neuroscience (Vraylar, Botox Therapeutic), oncology (Venclexta, Imbruvica) and aesthetics (Botox Cosmetic, Juvederm).

What is AbbVie's revenue?

FY2025 net revenues were $61.2 billion, up 8.6%. 2026 guidance was raised to approximately $67.6 billion in July 2026.

How many employees does AbbVie have?

AbbVie employed approximately 57,000 people in over 70 countries at December 31, 2025.

What is AbbVie's growth strategy?

It relies on Skyrizi and Rinvoq growing into the 2030s, neuroscience as a second engine, oncology and aesthetics launches, and business development including obesity, aiming for high single-digit revenue growth through 2029.

Who leads AbbVie?

Robert A. Michael is Chairman and CEO, Scott T. Reents is CFO, Jeffrey R. Stewart is Chief Commercial Officer and Roopal Thakkar leads R&D as Chief Scientific Officer.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)